Univariate and Multivariate Cox Proportional Hazards Analyses Examining Factors Associated with Time to Local CNS Progression
| . | Univariate . | Multivariate . | ||
|---|---|---|---|---|
| . | OR (95% CI) . | P-value . | OR (95% CI) . | P-value . |
| CDKN2A/B Co-del | 4.69 (1.57-14.01) | 0.006 | 4.07 (1.32-12.54) | 0.014 |
| Age | 1.05 (0.15-9.66) | 0.96 | ||
| Male (vs female) | 0.60 (0.19-1.96) | 0.40 | ||
| Preop KPS | 0.2 (0.03-2.2) | 0.19 | ||
| Minority | 1.29 (0.40-4.21) | 0.67 | ||
| Primary cancer | 0.84 | |||
| NSCLC | Reference | |||
| Breast | 1.73 (0.35-8.59) | |||
| Melanoma | 0.73 (0.12-4.39) | |||
| GI | 1.73 (0.29-10.38) | |||
| Gyn | 2.86 (0.48-17.15) | |||
| RCC | 2.68 (0.28-26.03) | |||
| Other | * (*) | |||
| No. total brain mets at surgery | 0.016 (6.3e-7-4.54) | 0.29 | ||
| Tumor volume | 3.94 (0.38-25.38) | 0.19 | ||
| Cystic | 0.82 (0.18-3.71) | 0.80 | ||
| Intratumoral hemorrhage | 0.39 (0.12-1.28) | 0.12 | ||
| Time from BM diagnosis to surgery | 9.22 (0.68-63.58) | 0.046 | 5.06 (0.31-43.25) | 0.19 |
| Presence of extracranial disease | 0.50 (0.17-1.50) | 0.22 | ||
| Side | 0.18 | |||
| Right | Reference | |||
| Left | 2.22 (0.67-7.37) | |||
| Midline | 6.98 (0.73-66.61) | |||
| Location | 0.54 | |||
| Frontal | Reference | |||
| Parietal | 2.60 (0.47-14.24) | |||
| Temporal | 1.82 (0.26-12.95) | |||
| Occipital | 4.78 (0.80-28.69) | |||
| Cerebellum | 2.68 (0.37-19.27) | |||
| GTR (vs STR) | 1.19 (0.26-5.38) | 0.82 | ||
| Prior intracranial radiotherapy | 2.65 (0.81-8.63) | 0.11 | ||
| Postoperative radiotherapy type | 0.94 | |||
| Local RT | Reference | |||
| WBRT | * (*) | |||
| None | 0.69 (0.09-5.32) | |||
| Postop checkpoint inhibitor | 0.7 (0.2-2.3) | 0.54 | ||
| Postop targeted inhibitor | 1.4 (0.5-4.1) | 0.56 | ||
| . | Univariate . | Multivariate . | ||
|---|---|---|---|---|
| . | OR (95% CI) . | P-value . | OR (95% CI) . | P-value . |
| CDKN2A/B Co-del | 4.69 (1.57-14.01) | 0.006 | 4.07 (1.32-12.54) | 0.014 |
| Age | 1.05 (0.15-9.66) | 0.96 | ||
| Male (vs female) | 0.60 (0.19-1.96) | 0.40 | ||
| Preop KPS | 0.2 (0.03-2.2) | 0.19 | ||
| Minority | 1.29 (0.40-4.21) | 0.67 | ||
| Primary cancer | 0.84 | |||
| NSCLC | Reference | |||
| Breast | 1.73 (0.35-8.59) | |||
| Melanoma | 0.73 (0.12-4.39) | |||
| GI | 1.73 (0.29-10.38) | |||
| Gyn | 2.86 (0.48-17.15) | |||
| RCC | 2.68 (0.28-26.03) | |||
| Other | * (*) | |||
| No. total brain mets at surgery | 0.016 (6.3e-7-4.54) | 0.29 | ||
| Tumor volume | 3.94 (0.38-25.38) | 0.19 | ||
| Cystic | 0.82 (0.18-3.71) | 0.80 | ||
| Intratumoral hemorrhage | 0.39 (0.12-1.28) | 0.12 | ||
| Time from BM diagnosis to surgery | 9.22 (0.68-63.58) | 0.046 | 5.06 (0.31-43.25) | 0.19 |
| Presence of extracranial disease | 0.50 (0.17-1.50) | 0.22 | ||
| Side | 0.18 | |||
| Right | Reference | |||
| Left | 2.22 (0.67-7.37) | |||
| Midline | 6.98 (0.73-66.61) | |||
| Location | 0.54 | |||
| Frontal | Reference | |||
| Parietal | 2.60 (0.47-14.24) | |||
| Temporal | 1.82 (0.26-12.95) | |||
| Occipital | 4.78 (0.80-28.69) | |||
| Cerebellum | 2.68 (0.37-19.27) | |||
| GTR (vs STR) | 1.19 (0.26-5.38) | 0.82 | ||
| Prior intracranial radiotherapy | 2.65 (0.81-8.63) | 0.11 | ||
| Postoperative radiotherapy type | 0.94 | |||
| Local RT | Reference | |||
| WBRT | * (*) | |||
| None | 0.69 (0.09-5.32) | |||
| Postop checkpoint inhibitor | 0.7 (0.2-2.3) | 0.54 | ||
| Postop targeted inhibitor | 1.4 (0.5-4.1) | 0.56 | ||
Abbreviations: KPS, Karnofsky Performance Scale; NSCLC, non-small cell lung cancer; GI, gastrointestinal; Gyn, gynecologic; RCC, renal cell carcinoma; GTR, gross total resection; STR, subtotal resection; CNS, central nervous system; RT, radiation therapy; WBRT, whole brain radiation therapy.
*No events for statistical analysis.
Univariate and Multivariate Cox Proportional Hazards Analyses Examining Factors Associated with Time to Local CNS Progression
| . | Univariate . | Multivariate . | ||
|---|---|---|---|---|
| . | OR (95% CI) . | P-value . | OR (95% CI) . | P-value . |
| CDKN2A/B Co-del | 4.69 (1.57-14.01) | 0.006 | 4.07 (1.32-12.54) | 0.014 |
| Age | 1.05 (0.15-9.66) | 0.96 | ||
| Male (vs female) | 0.60 (0.19-1.96) | 0.40 | ||
| Preop KPS | 0.2 (0.03-2.2) | 0.19 | ||
| Minority | 1.29 (0.40-4.21) | 0.67 | ||
| Primary cancer | 0.84 | |||
| NSCLC | Reference | |||
| Breast | 1.73 (0.35-8.59) | |||
| Melanoma | 0.73 (0.12-4.39) | |||
| GI | 1.73 (0.29-10.38) | |||
| Gyn | 2.86 (0.48-17.15) | |||
| RCC | 2.68 (0.28-26.03) | |||
| Other | * (*) | |||
| No. total brain mets at surgery | 0.016 (6.3e-7-4.54) | 0.29 | ||
| Tumor volume | 3.94 (0.38-25.38) | 0.19 | ||
| Cystic | 0.82 (0.18-3.71) | 0.80 | ||
| Intratumoral hemorrhage | 0.39 (0.12-1.28) | 0.12 | ||
| Time from BM diagnosis to surgery | 9.22 (0.68-63.58) | 0.046 | 5.06 (0.31-43.25) | 0.19 |
| Presence of extracranial disease | 0.50 (0.17-1.50) | 0.22 | ||
| Side | 0.18 | |||
| Right | Reference | |||
| Left | 2.22 (0.67-7.37) | |||
| Midline | 6.98 (0.73-66.61) | |||
| Location | 0.54 | |||
| Frontal | Reference | |||
| Parietal | 2.60 (0.47-14.24) | |||
| Temporal | 1.82 (0.26-12.95) | |||
| Occipital | 4.78 (0.80-28.69) | |||
| Cerebellum | 2.68 (0.37-19.27) | |||
| GTR (vs STR) | 1.19 (0.26-5.38) | 0.82 | ||
| Prior intracranial radiotherapy | 2.65 (0.81-8.63) | 0.11 | ||
| Postoperative radiotherapy type | 0.94 | |||
| Local RT | Reference | |||
| WBRT | * (*) | |||
| None | 0.69 (0.09-5.32) | |||
| Postop checkpoint inhibitor | 0.7 (0.2-2.3) | 0.54 | ||
| Postop targeted inhibitor | 1.4 (0.5-4.1) | 0.56 | ||
| . | Univariate . | Multivariate . | ||
|---|---|---|---|---|
| . | OR (95% CI) . | P-value . | OR (95% CI) . | P-value . |
| CDKN2A/B Co-del | 4.69 (1.57-14.01) | 0.006 | 4.07 (1.32-12.54) | 0.014 |
| Age | 1.05 (0.15-9.66) | 0.96 | ||
| Male (vs female) | 0.60 (0.19-1.96) | 0.40 | ||
| Preop KPS | 0.2 (0.03-2.2) | 0.19 | ||
| Minority | 1.29 (0.40-4.21) | 0.67 | ||
| Primary cancer | 0.84 | |||
| NSCLC | Reference | |||
| Breast | 1.73 (0.35-8.59) | |||
| Melanoma | 0.73 (0.12-4.39) | |||
| GI | 1.73 (0.29-10.38) | |||
| Gyn | 2.86 (0.48-17.15) | |||
| RCC | 2.68 (0.28-26.03) | |||
| Other | * (*) | |||
| No. total brain mets at surgery | 0.016 (6.3e-7-4.54) | 0.29 | ||
| Tumor volume | 3.94 (0.38-25.38) | 0.19 | ||
| Cystic | 0.82 (0.18-3.71) | 0.80 | ||
| Intratumoral hemorrhage | 0.39 (0.12-1.28) | 0.12 | ||
| Time from BM diagnosis to surgery | 9.22 (0.68-63.58) | 0.046 | 5.06 (0.31-43.25) | 0.19 |
| Presence of extracranial disease | 0.50 (0.17-1.50) | 0.22 | ||
| Side | 0.18 | |||
| Right | Reference | |||
| Left | 2.22 (0.67-7.37) | |||
| Midline | 6.98 (0.73-66.61) | |||
| Location | 0.54 | |||
| Frontal | Reference | |||
| Parietal | 2.60 (0.47-14.24) | |||
| Temporal | 1.82 (0.26-12.95) | |||
| Occipital | 4.78 (0.80-28.69) | |||
| Cerebellum | 2.68 (0.37-19.27) | |||
| GTR (vs STR) | 1.19 (0.26-5.38) | 0.82 | ||
| Prior intracranial radiotherapy | 2.65 (0.81-8.63) | 0.11 | ||
| Postoperative radiotherapy type | 0.94 | |||
| Local RT | Reference | |||
| WBRT | * (*) | |||
| None | 0.69 (0.09-5.32) | |||
| Postop checkpoint inhibitor | 0.7 (0.2-2.3) | 0.54 | ||
| Postop targeted inhibitor | 1.4 (0.5-4.1) | 0.56 | ||
Abbreviations: KPS, Karnofsky Performance Scale; NSCLC, non-small cell lung cancer; GI, gastrointestinal; Gyn, gynecologic; RCC, renal cell carcinoma; GTR, gross total resection; STR, subtotal resection; CNS, central nervous system; RT, radiation therapy; WBRT, whole brain radiation therapy.
*No events for statistical analysis.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
